Tamir Biotechnology Inc.

Tamir Biotechnology Inc. (ACEL)

Tamir Biotechnology, Inc., a development stage biopharmaceutical company, engages in the discovery and development of therapeutic drugs for the treatment of cancer and other pathological conditions. The company’s proprietary drug discovery and development program consists of therapeutics which are being developed from amphibian ribonucleases (RNases). ONCONASE ONCONASE, the company’s drug product candidate, has been evaluated in human clinical trials for the treatment of various forms of cancer. ONCONASE primarily affects exponentially growing malignant cells, with activity controlled through unique and specific molecular mechanisms. Marketing and Distribution Agreements Megapharm Ltd.: In May 2008, the company entered into a marketing, sales, and distribution agreement with Megapharm Ltd. for the commercialization of ONCONASE in Israel. BL&H Co. Ltd.: In January 2008, the company entered into a marketing and distribution agreement with BL&H Co. Ltd. for the commercialization of ONCONASE in Korea, Taiwan and Hong Kong. US Pharmacia: In July 2007, the company entered into a distribution and marketing agreement, with USP Pharma Spolka Z.O.O., an affiliate of US Pharmacia, pursuant to which the distributor was granted rights for the marketing, sales, and distribution of ONCONASE for use in oncology in Poland, Belarus, Ukraine, Estonia, Latvia, and Lithuania. GENESIS Pharma S.A.: In December 2006, the company entered into a distribution and marketing agreement with GENESIS Pharma S.A. (GENESIS), pursuant to which GENESIS was granted exclusive rights for the marketing, sales, and distribution of ONCONASE for use in oncology in Greece, Cyprus, Bulgaria, Romania, Slovenia, Croatia, Serbia, and the Former Yugoslavian Republic of Macedonia. Suppliers The company’s main supplier is Scientific Protein Laboratories LLC. History The company was incorporated in 1981. It was formerly known as Alfacell Corporation and changed its name to Tamir Biotechnology, Inc. in April 2010.